GeoWealth | $38,000,000 | (Aug 5, 2025)
Afaxys, Inc. | $8,000,000 | (Aug 5, 2025)
Comp AI | $2,600,000 | (Aug 5, 2025)
Certified by Founder
Lodge
Illimis Therapeutics
start up
Korea, Republic Of
- Seoul
- 15/07/2025
- Series B
- $42,000,000
Illimis Therapeutics is a platform-based Korean biotech company developing a chimeric fusion protein platform for neurodegenerative diseases such as Alzheimer’s. Our platform is differentiated by its ability to address the concerns of antibody-induced neuroinflammation and subsequent ARIA (Amyloid-Related Imaging Abnormalities) often observed from existing antibody drugs that utilize FcR-mediated phagocytosis of microglia, by utilizing TAM receptor, a novel phagocytic receptor expressed on the surface of glial cells.
- Industry Biotechnology Research
- Website www.illimistx.com
- LinkedIn https://www.linkedin.com/company/illimis-therapeutics/
Jeh Aerospace | $11,000,000 | (Aug 5, 2025)
Conversion | $28,000,000 | (Aug 5, 2025)
Approov Mobile Security | $6,641,429 | (Aug 5, 2025)
Q.ANT | $71,676,650 | (Aug 5, 2025)
BioConsortia, Inc. | $15,000,000 | (Aug 5, 2025)
Bidbus | $3,300,000 | (Aug 5, 2025)
Blue J | $122,000,000 | (Aug 5, 2025)
Deep Cogito | $13,000,000 | (Aug 5, 2025)
Streamline AI | $8,600,000 | (Aug 5, 2025)